EUVIMEDEUVIMED entdecken
Crossref

Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors

Andreas Blum iD, Dieter Dorsch, Nina Linde, Susanne Brandstetter, Hans-Peter Buchstaller iD, Michael Busch, Nina Glaser, Ulrich Grädler, Aaron Ruff, Carl Petersson, Hanno Schieferstein, Eva Sherbetjian und 1 weitere

Journal of Medicinal Chemistry · 23.02.2023 · 66 (4) · 2386-2395

DOI: 10.1021/acs.jmedchem.2c00851 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 02.02.2023. Verfasst von Andreas Blum und 12 weiteren Autor:innen. Beteiligte Einrichtung: Merck Healthcare KGaA, Frankfurter Str. 250, 64293Darmstadt, Germany. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Antineoplastic Agents, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of gastrointestinal stromal tumors (GISTs) driven by activating mutations in the KIT gene is a prime example of targeted therapy for treatment of cancer. The approval of the tyrosine kinase inhibitor imatinib has significantly improved patient survival, but emerging resistance under treatment and relapse is observed. Several additional KIT inhibitors have been approved; still, there is a high unmet need for KIT inhibitors with high selectivity and broad coverage of all clinically relevant KIT mutants. An imidazopyridine hit featuring excellent kinase selectivity was identified in a high-throughput screen (HTS) and optimized to the clinical candidate M4205 (IDRX-42). This molecule has a superior profile compared to approved drugs, suggesting a best-in-class potential for recurrent and metastatic GISTs driven by KIT mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsAntineoplastic AgentsGastrointestinal NeoplasmsHumansProto-Oncogene Proteins c-kitNeoplasm Recurrence, LocalImatinib MesylateMutationDrug Resistance, Neoplasm

Substanzen

Proto-Oncogene Proteins c-kitImatinib MesylateAntineoplastic Agents

Autor:innen und Institutionen

  • Merck Healthcare KGaA, Frankfurter Str. 250, 64293Darmstadt, Germany.

ORCID-Profile: Andreas Blum, Hans-Peter Buchstaller

Zitieren

APA

Blum, A., Dorsch, D., Linde, N., Brandstetter, S., Buchstaller, H. P., Busch, M., Glaser, N., Grädler, U., Ruff, A., Petersson, C., Schieferstein, H., Sherbetjian, E., & Esdar, C. (2023). Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors. Journal of Medicinal Chemistry, 66(4), 2386-2395. https://doi.org/10.1021/acs.jmedchem.2c00851

Vancouver

Blum A, Dorsch D, Linde N, Brandstetter S, Buchstaller HP, Busch M, et al. Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors. Journal of Medicinal Chemistry. 2023;66(4):2386-2395. doi:10.1021/acs.jmedchem.2c00851

BibTeX
@article{Blum2023,
  author = {Blum, Andreas and Dorsch, Dieter and Linde, Nina and Brandstetter, Susanne and Buchstaller, Hans-Peter and Busch, Michael and Glaser, Nina and Grädler, Ulrich and Ruff, Aaron and Petersson, Carl and Schieferstein, Hanno and Sherbetjian, Eva and Esdar, Christina},
  title = {Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {4},
  pages = {2386--2395},
  doi = {10.1021/acs.jmedchem.2c00851}
}
Kostenlos starten →